How to Get Crestor (Rosuvastatin) in Minnesota

Rosuvastatin Prescribing in Minnesota: Who Can Write the Script

Any clinician holding an active Minnesota license can prescribe rosuvastatin. That includes physicians (MD/DO), nurse practitioners (NP), and physician assistants (PA). Minnesota Nurse Practice Act provisions grant NPs full prescriptive authority without a collaborative agreement, a policy the American Association of Nurse Practitioners has documented across state-level scope-of-practice analyses [1]. PAs prescribe under their supervising physician's delegation agreement, though supervision can be remote.

For patients without an established primary care provider, urgent care clinics and retail health clinics (MinuteClinic, M Health Fairview) across the Twin Cities and Greater Minnesota can evaluate lipid panels and initiate statin therapy. The ACC/AHA 2018 Cholesterol Clinical Practice Guideline recommends starting moderate- to high-intensity statin therapy for adults with LDL-C persistently at or above 190 mg/dL, those with clinical ASCVD, or patients aged 40 to 75 with diabetes [2]. Rosuvastatin at 20 to 40 mg daily qualifies as high-intensity therapy under that framework.

A physician or NP visit specifically for statin initiation typically runs 15 to 20 minutes, covering cardiovascular risk calculation (pooled cohort equations), baseline labs, and medication selection.

Telehealth Access to Rosuvastatin in Minnesota

Minnesota legalized telehealth prescribing for non-controlled medications, and rosuvastatin falls squarely within that scope. The Minnesota Board of Medical Practice requires that telehealth providers either hold a Minnesota medical license or register through the Interstate Medical Licensure Compact [3]. Platforms such as HealthRX, Lemonaid Health, and PlushCare offer statin prescriptions via synchronous video or audio visits.

A telehealth statin visit follows the same clinical workflow as in-person care. The provider reviews recent lab work (or orders new labs through a local draw site such as Quest Diagnostics or Labcorp, both of which operate multiple locations across Hennepin, Ramsey, Dakota, and St. Louis counties), assesses 10-year ASCVD risk using the pooled cohort equations published by the AHA, and selects a statin intensity [4].

Prescriptions generated via telehealth are transmitted electronically to any Minnesota pharmacy the patient chooses. E-prescribing is standard. Most patients receive a filled prescription within 24 to 48 hours of their telehealth visit, depending on pharmacy workload.

One practical advantage of telehealth: follow-up lipid checks at 4 to 12 weeks (recommended per ACC/AHA monitoring guidance) can happen via a brief video visit after the patient completes a repeat fasting lipid panel locally [2]. This eliminates a second office trip.

Lab Work Required Before Starting Rosuvastatin

Before prescribing rosuvastatin, clinicians in Minnesota follow the same evidence-based protocol used nationally. The 2018 ACC/AHA guideline specifies the following baseline labs [2]:

Fasting lipid panel. Total cholesterol, LDL-C, HDL-C, and triglycerides. A 9- to 12-hour fast is standard, though non-fasting panels are acceptable for initial screening per the 2019 ESC/EAS dyslipidemia guidelines [5].

Hepatic transaminases (ALT). The rosuvastatin prescribing information requires baseline liver function assessment. Clinically significant transaminase elevation (greater than 3 times the upper limit of normal) is a contraindication [6]. The FDA label, available through accessdata.fda.gov, specifies this threshold [6].

Fasting glucose or HbA1c. Statins carry a modest risk of new-onset diabetes. The JUPITER trial (N=17,802) showed rosuvastatin 20 mg daily was associated with a physician-reported diabetes incidence of 3.0% vs. 2.4% on placebo over a median 1.9 years of follow-up [7]. Baseline glucose screening helps identify patients already near the diabetic threshold.

Creatine kinase (CK). Not routinely required, but useful if the patient reports prior statin-related myalgia or has risk factors for myopathy (hypothyroidism, renal impairment, Asian ancestry requiring lower starting doses per the FDA label) [6].

Quest Diagnostics and Labcorp both offer walk-in fasting lipid panels across Minnesota, typically returning results within 1 to 2 business days.

Minnesota Medicaid Coverage and Prior Authorization

Minnesota Medical Assistance (Medicaid) covers rosuvastatin for hyperlipidemia and ASCVD prevention. Generic rosuvastatin is on the Minnesota Medicaid preferred drug list. Brand Crestor requires prior authorization.

The prior authorization process for brand Crestor in Minnesota Medicaid typically requires:

1. Documentation of a trial and therapeutic failure on generic rosuvastatin (or documented intolerance such as myalgia, elevated CK, or hepatic enzyme elevation)
2. Prescriber's clinical justification letter
3. Recent lipid panel results showing continued need for high-intensity statin therapy
4. Diagnosis code (ICD-10 E78.0 for pure hypercholesterolemia or I25.10 for atherosclerotic heart disease)

Turnaround for PA decisions is 24 hours for standard requests and 4 hours for urgent requests under Minnesota statute [8]. The Minnesota Department of Human Services publishes current formulary and PA criteria on its website.

Generic rosuvastatin, because it sits on the preferred tier, typically requires no prior authorization. Copays for Minnesota Medicaid enrollees on generic preferred drugs range from $1 to $3 per fill [8].

Cost of Rosuvastatin in Minnesota

Generic rosuvastatin is one of the least expensive branded-to-generic conversions in cardiovascular medicine. Crestor lost U.S. Patent exclusivity in 2016, and generic competition drove prices down sharply.

Current retail pricing at Minnesota pharmacies for a 30-day supply of generic rosuvastatin (most commonly prescribed at 10 mg or 20 mg):

Generic rosuvastatin 10 mg (30 tablets) typically costs $4 to $10 without insurance at major chains. Costco, Walmart, and several Minnesota independent pharmacies include rosuvastatin on $4 generic lists. With commercial insurance, copays frequently land at $0 to $5 on the lowest formulary tier.

Brand Crestor, by contrast, carries a cash price of approximately $350 to $400 for 30 tablets. The cost differential explains why 95% of rosuvastatin prescriptions dispensed in the U.S. Are filled as generic, according to IQVIA prescription data trends in statin utilization [9].

The JUPITER trial demonstrated that rosuvastatin 20 mg reduced major cardiovascular events by 44% (HR 0.56; 95% CI, 0.46 to 0.69; P<0.00001) in apparently healthy individuals with elevated high-sensitivity C-reactive protein [7]. At $4 to $10 per month for generic rosuvastatin, the cost-effectiveness profile is among the most favorable of any cardiovascular medication available in Minnesota, a point reinforced by the 2022 cost-effectiveness analysis published in JAMA Cardiology [10].

Pharmacy Options Across Minnesota

Minnesota residents can fill rosuvastatin prescriptions at chain pharmacies (CVS, Walgreens, Walmart, Target/CVS), independent pharmacies, health system outpatient pharmacies (Mayo Clinic Pharmacy, M Health Fairview, Essentia Health), and mail-order pharmacies.

Mail-order pharmacies. Most Minnesota commercial insurers and Medicare Part D plans offer 90-day mail-order fills for rosuvastatin at reduced copays. Express Scripts, Optum Rx, and CVS Caremark all serve Minnesota patients. A 90-day supply of generic rosuvastatin via mail order commonly costs $8 to $15 total.

503A compounding pharmacies. Minnesota licenses 503A compounding pharmacies under the Minnesota Board of Pharmacy, consistent with FDA guidance on 503A compounding [11]. These pharmacies can compound rosuvastatin into alternative dosage forms (suspensions for patients with dysphagia, for example) based on a patient-specific prescription. They cannot, however, compound copies of commercially available strengths without a documented clinical need (allergy to an inactive ingredient, pediatric dosing not available commercially).

Specialty considerations. Rosuvastatin is not a specialty drug. It does not require specialty pharmacy dispensing, cold chain shipping, or REMS enrollment. Any licensed pharmacy in Minnesota can dispense it [6].

Transferring a Crestor Prescription to Minnesota

Patients relocating to Minnesota or traveling within the state can transfer an existing rosuvastatin prescription from another state. Minnesota Board of Pharmacy rules permit inter-state prescription transfers for non-controlled substances. The process is straightforward.

The patient contacts their new Minnesota pharmacy, provides the original pharmacy's name and phone number, and the receiving pharmacist initiates the transfer call. Electronic transfer is also permitted. The original prescription must have remaining refills. If no refills remain, the patient needs a new prescription from a Minnesota-licensed provider, which a telehealth visit can accomplish within a day.

One nuance: some insurers require the patient to update their home address and pharmacy preference in their plan portal for the new pharmacy to bill correctly. This is an insurance administrative step, not a pharmacy or regulatory barrier.

Rosuvastatin Dosing and Monitoring After Initiation

The ACC/AHA guideline recommends rechecking a fasting lipid panel 4 to 12 weeks after starting or adjusting statin therapy [2]. The target is a percentage reduction in LDL-C rather than a fixed LDL-C number for primary prevention. High-intensity statin therapy (rosuvastatin 20 to 40 mg) is expected to reduce LDL-C by 50% or more from baseline [2].

For secondary prevention in patients with established ASCVD, the 2018 AHA/ACC guideline recommends maximally tolerated statin therapy, with consideration of ezetimibe or a PCSK9 inhibitor if LDL-C remains at or above 70 mg/dL [2].

Rosuvastatin dosing in Minnesota follows the standard FDA-approved range [6]:

• Primary prevention, moderate intensity: 5 to 10 mg daily
• Primary prevention, high intensity: 20 to 40 mg daily
• Secondary prevention (ASCVD): 20 to 40 mg daily
• Asian patients: Start at 5 mg daily due to pharmacokinetic differences documented in the FDA label [6]
• Severe renal impairment (CrCl <30 mL/min): Start at 5 mg, max 10 mg daily [6]

Routine CK monitoring is not recommended unless the patient develops muscle symptoms. Hepatic function should be checked if clinically indicated (jaundice, fatigue, dark urine) but routine repeat ALT monitoring is no longer recommended per the 2012 FDA safety communication that removed the periodic liver test requirement for statins [12].

Clinical Evidence Supporting Rosuvastatin

The evidence base for rosuvastatin is extensive. Key trials that inform prescribing decisions in Minnesota and nationally:

JUPITER (2008). This landmark trial randomized 17,802 apparently healthy men (50 years and older) and women (60 years and older) with LDL-C below 130 mg/dL and hsCRP of 2.0 mg/L or higher to rosuvastatin 20 mg or placebo [7]. The trial was stopped early at a median of 1.9 years because rosuvastatin reduced the primary composite endpoint (MI, stroke, arterial revascularization, hospitalization for unstable angina, cardiovascular death) by 44%. LDL-C dropped 50% and hsCRP dropped 37% in the rosuvastatin group [7].

METEOR (2007). Rosuvastatin 40 mg slowed progression of carotid intima-media thickness (CIMT) compared to placebo in low-risk patients with subclinical atherosclerosis over 2 years, as published in JAMA [13].

ASTEROID (2006). Rosuvastatin 40 mg daily produced regression of coronary atherosclerosis measured by intravascular ultrasound (IVUS) after 24 months, with a mean change in percent atheroma volume of -0.98% (P<0.001), reported in JAMA [14].

The Endocrine Society and AHA/ACC both position rosuvastatin as a first-line high-intensity statin, alongside atorvastatin 40 to 80 mg [2][15].

Minnesota-Specific Regulatory Notes

Minnesota maintains a strong telehealth regulatory environment. The state does not impose an in-person visit requirement before telehealth prescribing of non-controlled medications like rosuvastatin. The Minnesota Telemedicine Act (Minn. Stat. § 62A.672) requires commercial insurers to cover telehealth services at parity with in-person visits, which means patients pay the same copay whether they see a prescriber via video or in the office.

Minnesota also participates in the Interstate Medical Licensure Compact, allowing physicians licensed through the Compact to practice telehealth for Minnesota patients without obtaining a separate Minnesota license [3]. This expands the pool of available prescribers for patients in rural Minnesota counties where in-person lipid management specialists may be limited.

The Minnesota Board of Pharmacy requires all pharmacies dispensing in the state (including out-of-state mail-order pharmacies) to hold a Minnesota nonresident pharmacy license, ensuring patient safety oversight for all rosuvastatin dispensing regardless of the pharmacy's physical location [16].